# Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 1 Hepatitis C Virus Infection Patients

> **NCT04001608** · PHASE3 · UNKNOWN · sponsor: **Ginkgopharma CO., LTD** · enrollment: 206 (actual)

## Conditions studied

- Hepatitis C Virus Infection

## Interventions

- **DRUG:** Seraprevir
- **DRUG:** Sofosbuvir

## Key facts

- **NCT ID:** NCT04001608
- **Lead sponsor:** Ginkgopharma CO., LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10-17
- **Primary completion:** 2019-07-31
- **Final completion:** 2019-11-30
- **Target enrollment:** 206 (ACTUAL)
- **Last updated:** 2019-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04001608

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04001608, "Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 1 Hepatitis C Virus Infection Patients". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04001608. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*